Ready to benefit from training: Heterologous effects of early life immunization

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 109, Issue 1, 2014, Pages 3-4

  Levy, Orly ^a   Levy, Ofer ^b,c  

^a Buckingham Browne and Nichols School   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

heterologous immunity; Infant; Newborn; Non specific effect; Trained immunity; Vaccine

Indexed keywords

BCG VACCINE; LIVE VACCINE; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; IMMUNOLOGICAL ADJUVANT; TOLL LIKE RECEPTOR;

ARTICLE; CANDIDIASIS; CHORIOAMNIONITIS; CYTOKINE RESPONSE; HOST RESISTANCE; HUMAN; IMMUNITY; IMMUNIZATION; LISTERIOSIS; MACROPHAGE; MEMORY CELL; MEMORY T LYMPHOCYTE; NONHUMAN; SALMONELLA; SCHISTOSOMIASIS MANSONI; STAPHYLOCOCCUS INFECTION; TRAINED IMMUNITY; TUBERCULOSIS; ADAPTIVE IMMUNITY; AGONISTS; ANIMAL; COMMUNICABLE DISEASE; DRUG EFFECTS; FEMALE; GENETIC EPIGENESIS; GENETICS; HETEROLOGOUS IMMUNITY; IMMUNOLOGY; INNATE IMMUNITY; MOUSE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE; TRENDS;

MUS;

ADAPTIVE IMMUNITY; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BCG VACCINE; COMMUNICABLE DISEASES; EPIGENESIS, GENETIC; FEMALE; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNITY, INNATE; IMMUNIZATION; MICE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; TOLL-LIKE RECEPTORS;

EID: 84928879978     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1093/trstmh/tru185     Document Type: Article

References (13)

1. Liu L, Johnson HL, Cousens S et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 2012;379:2151-61.
2. Pettengill M, van Haren SD, Levy O. Soluble mediators regulating immunity in early life. Front Immunol 2014;5:457.
3. Elahi S, Ertelt JM, Kinder JM et al. Immunosuppressive CD71 erythroid cells compromise neonatal host defence against infection. Nature 2013;504:158-62.
4. Dowling DJ, Levy O. Ontogeny of early life immunity. Trends Immunol 2014;35:299-310.
5. Kumar P, Tyagi R, Das G, Bhaskar S. Mycobacterium indicus pranii and Mycobacterium bovis BCG lead to differential macrophage activation in TLR-dependent manner. Immunology 2014;43:258-68.
6. Dowling DJ, Tan Z, Prokopowicz ZM et al. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes. PLoS One 2013;8:e58164.
7. Wynn JL, Scumpia PO, Winfield RD et al. Defective innate immunity predisposes murine neonates to poor sepsis outcome but is reversed by TLR agonists. Blood 2008;112:1750-8.
8. Strunk T, Doherty D, Jacques A et al. Histologic chorioamnionitis is associated with reduced risk of late-onset sepsis in preterm infants. Pediatrics 2012;129:e134-41.
9. Netea MG. Training innate immunity: the changing concept of immunological memory in innate host defence. Euro J Clin Invest 2013;43:881-4.
10. Kleinnijenhuis J, Quintin J, Preijers F et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012,109:17537-42.
11. Aaby P, Benn CS. Saving lives by training innate immunity with bacille Calmette-Guerin vaccine. Proc Natl Acad Sci USA 2012;109:17317-8.
12. Sorup S, Benn CS, Poulsen A et al. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA 2014;311:826-35.
13. Levy O, Netea MG. Innate immune memory: implications for development of pediatric immunomodulatory agents and adjuvanted vaccines. Pediatr Res 2014;75:184-8.